With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.54761-04-5,Ytterbium(III) trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.
To 5 (0.131 g, 1.0 mmol) and Yb(OTf)3 (0.124 g, 0.20 mmol) in CH2Cl2 (1.5 mL) under argon was added methyl vinyl ketone 22(0.162 mL, 2 mmol). The reaction mixture was stirred at rt overnight and concentrated in vacuo. Purification by silica gel chromatography (1:1, EtOAc:hexane, to 100%, EtOAc, as eluent) afforded 24 asa white solid (0.051 g, 25%) and 23 as a yellow oil (0.128 g, 37%): Rf.0.23 (1:1, EtOAc:methanol, as eluent); 1H NMR (700 MHz, CDCl3)d 9.12 (br s, 1H), 7.87 (dd, J7.6, 1.1 Hz, 1H), 7.72 (td, J7.6, 1.1 Hz,1H), 7.47 (td, J7.6, 1.1 Hz, 1H), 7.35 (dd, J7.6, 1.1 Hz, 1H), 4.32 (t,J6.0 Hz, 2H), 4.14 (t, J8.1 Hz, 2H), 3.29 (t, J6.0 Hz, 2H), 3.27 (t,J8.1 Hz, 2H), 2.23 (s, 3H) ppm; 13C NMR (176 MHz, CDCl3) d 206.2,168.1, 138.6, 136.4, 134.7, 128.7 (q, J285 Hz), 124.7, 121.9, 119.4,116.8, 55.6, 49.2, 40.1, 30.1, 25.5; IR nmax (thin film) 1714 (C]O),1661 (C]N) cm1; LRMS (TOF ES), 203.5 (100%) [MH], 201.7(70%), 132.1 (25%); LRMS (TOF ES-), 149.0 (100%) [OTf]; HRMS(FTMS ES) calculated for C13H15NOH, 202.12264; found202.12262; HRMS (FTMS ES-), calculated for CF3O3Se, 148.95257;found 148.95217.
54761-04-5 Ytterbium(III) trifluoromethanesulfonate 2733225, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Article; Girling, P. Ricardo; Batsanov, Andrei S.; Calow, Adam D.J.; Shen, Hong C.; Whiting, Andrew; Tetrahedron; vol. 72; 8; (2016); p. 1105 – 1113;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI